@article{2599484cfd664eb8bd66308c6c3a85fc,
title = "Evolving role of obeticholic acid in primary biliary cholangitis",
author = "Cynthia Levy",
note = "Funding Information: Abbreviations: ALP, alkaline phosphatase; BAs, bile acids; FDA, U.S. Food and Drug Administration; FGF19, fibroblast growth factor 19; FXR, farnesoid X receptor; HDLs, high-density lipoproteins; LDLs, low-density lipoproteins; OCA, obeticholic acid; PBC, primary biliary cholangitis; PPAR, peroxisome proliferator-activated receptor; TGR5, G-protein-coupled receptor-1; UDCA, ursodeoxycholic acid. Received November 1, 2017; accepted December 2, 2017. Copyright VC 2017 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.29726 Potential conflict of interest: Dr. Levy consults for and received grants from Intercept and Novartis. She consults for Target Pharma Solutions and Cara Therapeutics. She received grants from GlaxoSmithKline, Tobira, NGM, Enanta, HighTide, Genfit, Gilead and Genkyotek.",
year = "2018",
month = may,
doi = "10.1002/hep.29726",
language = "English (US)",
volume = "67",
pages = "1666--1668",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",
}